Human Xtensions 2025: After Selling the Business, the Real Question Is Whether There Is Enough Time for the Next Deal

Getting To Know The Company

Human Xtensions should no longer be read as a medical-device company. After the first stage of the asset sale was completed, what remains on the exchange is a listed shell with limited cash, no real operating activity, and a management team trying to inject a new business into it before the clock runs out. What is actually working right now? The cost base has been cut close to the floor, there is no financial debt, and the company still has a public shell that can serve as a transaction platform. The active bottleneck is not technology or sales. It is simpler: cash, time, and the ability to turn a non-binding idea into a binding deal.

That is why a superficial reading of the report is misleading. Gross profit is positive, the loss shrank almost to nothing by historical standards, and research and selling expenses disappeared. That is the wrong read. This is not a picture of a business that repaired itself. It is a company that sold the business, shut down almost all operating spending lines, and relied in 2025 on an inventory write-down reversal and a small gain on the asset sale. Even the positive working capital does not mean there is a large safety cushion. Part of current assets is a receivable tied to the sale, not a live business that generates cash.

This matters now because in February 2026 the company signed a non-binding memorandum to acquire a business communications activity built around artificial intelligence. At first glance that sounds like a recovery story. At second glance it is almost a full reset: the target shareholders are expected to own about 79.18% of the company, current shareholders only about 15.84%, and the investment banker another 4.99%, all subject to a pre-closing equity raise of at least NIS 19 million. In other words, Human Xtensions is still looking for its next business, but if it finds it, current shareholders remain a clear minority in a new company.

At a share price of 19 agorot and 26.8 million issued shares, the market value is roughly NIS 5.1 million. That makes this a story about access to a public shell, not about current operating value. There is also a clear actionability constraint: the shares were moved to the preservation list in July 2025, and a return to the main list is itself a formal condition in the new transaction path. So even if value is eventually created here, the path from theoretical value to accessible value for common shareholders is still far from clean.

Quick Economic Map

This chart captures the reset well. Revenue was already close to zero in 2024 and disappeared entirely in 2025. The operating loss also collapsed, but not because the business healed. It collapsed because the old business was sold, the cost base was cut, and the report shifted from a struggling medtech commercialisation story to a listed shell carrying mainly the costs of maintaining the public vehicle.

Events And Triggers

The old transaction is still not fully behind the company

First trigger: the first stage of the asset sale was completed on August 18, 2025, and the company received the consideration for the first two milestones together, $800 thousand plus VAT, net of advances used to pay expenses on behalf of the buyer. In accounting terms that became NIS 2.707 million of cash and NIS 622 thousand of deferred consideration, based on the discounted value of what remains.

But what really matters is what has not yet happened. The second stage is still not complete, and the remaining $200 thousand is not supposed to flow directly to the company now. It first goes into escrow at the second closing and is released only at the third closing, 12 months after the first closing, if the agreed conditions are met. On top of that, the indemnity mechanism allows the buyer to recover up to $200 thousand out of that escrow. So anyone treating the remaining consideration as almost-cash is missing the core point: accounting has moved ahead, but economic access to the cash is still conditional.

This is already the second reset attempt

Second trigger: the new AI-related memorandum was signed in February 2026, but it is not the first reset route the company tried. During 2025 the company also signed a non-binding memorandum with a Canadian biogas and energy company, and that negotiation was terminated in June 2025. That matters because it shows the company is actively searching, but it also shows that moving from a memorandum to a signed transaction is far from automatic.

In other words, the current memorandum is an option, not a fact. The parties gave themselves a 60-day window to work toward a detailed binding agreement. What supports the thesis is that the framework is already fairly specific. What weakens it is that the practical list of conditions is still long: due diligence, valuation, financing, regulatory approvals, shareholder approval, exchange approvals, and a route back to the main list.

This chart makes the issue impossible to miss. The new transaction, if completed, is not designed to repair old Human Xtensions. It is designed to build a new company inside the shell, with economic control sitting overwhelmingly with the target owners and the new capital.

The management cuts say something, but not enough

Third trigger: as of the report date the company has just one employee left, the CEO who also serves as CFO. After year-end, the CEO initiated a voluntary reduction of NIS 10 thousand per month in his monthly compensation cost for three months starting in February 2026. At the same time, the chairman received 516,646 non-tradable options in February 2026 with a fair value of roughly NIS 80 thousand.

The signal is double-sided. On one hand, management and the board are clearly running the company in an extremely lean form and are trying to preserve every shekel. On the other hand, when a company needs a three-month salary cut at the CEO level to extend its runway a little, that also tells you that the room for error is genuinely narrow.

Efficiency, Profitability, And Competition

The central story of 2025 is not operational improvement. It is report clean-up after the business was sold. Anyone trying to read these numbers as though the company still operates a business will reach the wrong conclusion.

Gross profit is positive, but there is no revenue

In 2025 the company recorded zero revenue and still finished the year with NIS 1.53 million of gross profit. That sounds paradoxical, and it is. The main reason is a NIS 1.465 million reversal of inventory impairment after the company updated the fair value of assets held for sale to reflect the expected sale consideration. Alongside that, it recorded cost of revenues of NIS 65 thousand, mainly due to the warranty provision line.

So the 2025 gross profit does not describe a live business. It describes an accounting clean-up around the asset sale. The NIS 73 thousand of other income is also a small gain on the sale, not new operating profit. If someone looks at the gross line or the smaller loss and concludes that the company is profitable again, they are reading an accounting bridge rather than business economics.

The cost base was cut almost to the floor, and cash still burns

Research and development expenses fell from NIS 13.1 million in 2024 to zero. Sales and marketing fell from NIS 3.3 million to zero. General and administrative expenses fell from NIS 6.8 million to NIS 2.8 million, a 58.6% drop. That is a real reset, and it explains why operating loss narrowed by 95.3% to NIS 1.2 million.

But again the deeper layer matters. Inside general and administrative expenses, the company still carried NIS 1.465 million of compensation and NIS 1.489 million of professional services in 2025. Put simply, even after becoming a shell, the cost of maintaining a public company, supporting transaction work, and running the legal entity still consumes meaningful cash.

The chart shows the move from a development and commercialisation company to a vehicle that mainly carries the corporate layer. That is much cheaper than before, but it also does not generate revenue today.

The split inside 2025 shows why the annual result looks cleaner than it is

In the semiannual disclosure, the first half of 2025 showed total profit of NIS 523 thousand, while the second half showed a total loss of NIS 1.795 million. That matters because it tells you the full-year number looks cleaner mainly because of sale-related accounting effects, while the back half, when the company was already deeper into its shell phase, moved back to reflecting the cost of existence without an operating engine.

The real competition is for capital, a target, and credibility

At this stage Human Xtensions has no operating moat. There is no product, no active sales engine, no ongoing customer base, and no live value chain. The real competition is the ability to bring a credible target and outside financing into the shell before the runway ends.

And that is not an easy competition. The company has a market value of roughly NIS 5 million and is trying to close a deal in which the target must be valued at no less than NIS 100 million while simultaneously raising NIS 19 million before closing. That gap makes the bargaining power very clear: it sits with the target owners, the investors who will fund the reset, and the regulators and exchange gatekeepers who must approve the path.

Cash Flow, Debt, And Capital Structure

The right way to read Human Xtensions today is through all-in cash flexibility, not through normalised cash generation. There is no live recurring business from which you can strip out growth capex and talk about maintenance earnings power. There is a listed shell that survives or fails based on how much cash remains after actual uses.

The 2025 cash bridge is worse than the accounting loss suggests

The company started 2025 with NIS 4.025 million of cash and cash equivalents and finished with only NIS 991 thousand. Operating cash flow was negative NIS 5.901 million. Investment activity brought in NIS 2.867 million, mainly from the asset sale and the release of deposits. There was no cash flow from financing activity in 2025.

This chart tells a more important story than the net loss line. Total loss for the year was NIS 1.272 million, but cash declined by NIS 3.034 million. In other words, even after the business sale and the sharp cut in expenses, the public shell still consumed materially more cash than the profit and loss statement alone would imply.

Working capital is positive, but its quality is only moderate

As of December 31, 2025 the company had NIS 1.934 million of current assets against NIS 444 thousand of current liabilities, for positive working capital of NIS 1.49 million. At first glance that sounds reassuring. At second glance, NIS 868 thousand of current assets were receivables and other current assets, and NIS 604 thousand of that amount was specifically tied to the asset sale. So part of the working-capital cushion comes from the economics of exiting the old business, not from a business currently generating cash.

The implication is simple: the balance sheet is cleaner than before, but the flexibility is smaller than the working-capital line suggests. Once you look at asset quality instead of just totals, you see that a meaningful part of the cushion depends on sale-related balances rather than live operating cash creation.

There is no financial debt, and pressure is still real

To the company’s credit, one thing should be said clearly: by year-end 2025 there was no financial debt, no lease liability left after rights were transferred to the buyer, and equity was still positive at NIS 1.49 million. That is not a bad starting point for a listed shell.

But this is the core issue: a clean starting point is not the same as a comfortable starting point. The board explicitly says that if the old sale is not fully completed and no equity raise is carried out, the company’s cash is expected to last only until May 2026. The auditor goes further by flagging a going-concern issue because currently available sources are not sufficient for 12 months from the approval date of the financial statements. So what looks like an orderly balance sheet is in fact a fairly short time window in which the company must secure either financing or a transaction.

Outlook And What Comes Next

Before going into the detail, here are four non-obvious findings that explain how 2026 should be read:

• First finding: the memorandum is not a financing solution. It is a condition that itself requires financing. Without a pre-raise of at least NIS 19 million, the deal does not reach closing.
• Second finding: the remaining consideration from the old sale is not the same as free cash. The final $200 thousand is subject both to milestones and to an indemnity mechanism.
• Third finding: current shareholders are not underwriting a recovery of the old business. They are underwriting a path in which their ownership could fall to only 15.84%.
• Fourth finding: the annual report looks cleaner, but the board itself sets a clear time ceiling, with cash lasting only until May 2026 absent the old-sale completion and a capital raise.

The window for a detailed agreement is very short

The memorandum was signed on February 19, 2026 and gives the parties 60 days to work toward a detailed binding agreement. That means the initial window is short by design. If no detailed agreement is signed within that period, the memorandum can be cancelled. So in the immediate term, the market should not be looking for strategy language. It should be watching one simple signal: does the memorandum move into a binding contract, or does it remain another idea on paper.

Even if a detailed agreement is signed, the condition chain remains long. There is a third-party valuation, with a minimum NIS 100 million value for the target or a need to renegotiate. There are regulatory and third-party approvals, including tax and communications approvals if needed. There is a shareholder vote, approval to list the newly issued shares, and an exchange path back to the main list. None of this makes the path impossible. It does make it crowded.

Financing is the real economic test

The single most important number in the new transaction path is NIS 19 million. Not 79.18%, not NIS 100 million, and not 60 days. NIS 19 million. Without that amount in the company’s account, the transaction fails a core closing condition.

That matters because it shows what Human Xtensions is really offering the market right now. It is not medical-device technology, and it is not even an AI activity already under its control. It is the right to participate in funding a listed shell on its way toward a reverse-merger style reset. If the money arrives, the deal can become serious. If it does not, even a well-framed memorandum is not worth much.

The question is not just whether value is created, but who keeps it

If the new transaction is completed, current shareholders are expected to be left with only 15.84% of the equity after the pre-raise and the banker allocation. So even if the deal creates operating value, current shareholders only retain a small slice of it. That is not automatically a reason to reject the deal, because the alternative of no deal may be worse. But it is a reason to understand that the company is not on a path of recovering existing value. It is on a path of replacing the economic base at the price of deep dilution.

2026 looks like a survival bridge year

If the coming year needs a name, it is not a breakout year. It is not really a stabilisation year either. It is a survival bridge year. The company’s task over the next 2 to 4 quarters is not to show growth. It is to prove it has a path to fund itself until a new deal closes, tie off the loose ends of the old asset sale, and convert a memorandum into a funded binding structure.

What could improve the read? A detailed agreement, a successful pre-raise, visible progress on the second stage of the old sale, and lower uncertainty around the remaining $200 thousand. What would weaken it? Any financing delay, any valuation shortfall below the agreed floor, failure to meet the memorandum timeline, or evidence that cash is burning faster than expected.

Risks

The going-concern risk is not a footnote

The going-concern flag here is not just cautious wording. The auditor says current sources are not enough for 12 months from the statement approval date, and the board itself says cash lasts only until May 2026 in the no-raise and no-completion scenario. That is the central risk, and every other risk sits on top of it.

The remaining consideration from the old sale is still conditional

The first stage is done, but the sale is not fully done. Any delay in the second stage, any dispute about compliance with undertakings, or any indemnity claim can reduce or delay access to the final $200 thousand. That is why the residual consideration should not be treated as certain cash.

The new reset deal may solve one problem and create another

If completed, the new transaction addresses part of the company’s existential problem by injecting a business and capital. But it opens a second problem, very deep dilution. So the move is clearly two-sided: it may preserve the public vehicle and bring in activity, but it may also leave current public shareholders with only a limited economic share of what comes next.

The preservation list and liquidity add a practical constraint

Even for readers who are positive on the reset option, the company remains on the preservation list. A return to the main list requires an exchange-level path and is itself a condition in the new transaction. So the challenge here is not only business or financing. It is also market structure. Value created on paper still has to become accessible and tradable.

Conclusions

Human Xtensions finished 2025 in a cleaner state, but not in a stronger one. The old business is largely out, the cost base has been cut hard, and the balance sheet has no financial debt. On the other side, cash fell below NIS 1 million, the auditor raised a going-concern issue, and the company’s main option is a new transaction that would require both time and deep dilution.

At the highest level, the market should not be asking whether 2025 looks better. It should be asking whether the company still has enough time, money, and credibility to move from a maintained shell to a funded new deal.

Current thesis: Human Xtensions is now a listed shell with a short runway, and shareholder value depends far less on reported 2025 numbers than on whether management can close a new transaction before cash runs down.

What changed: the company is no longer trying to keep a weak medtech business alive. After selling the assets, the story shifted from failed commercialisation to an existential search for replacement activity and capital.

Counter thesis: the cost base is already extremely lean, there is no financial debt, and if management can quickly convert the memorandum into a funded binding deal, the public shell may still be worth more than the current market value despite the dilution.

What could change the market reading over the short and medium term: a binding detailed agreement, a successful pre-raise on credible terms, and real progress on both the old sale mechanics and the route back to the main list.

Why this matters: because at this point shareholders do not own a business. They own a leveraged option on management’s ability to turn a cash-light listed shell into a funded operating platform before time defeats the story.

What must happen in the next 2 to 4 quarters for the thesis to improve is clear: sign a binding agreement, close the capital raise, make real progress on the old-sale milestones, and extend the effective cash runway. What would undermine it is any delay showing that the company can produce memoranda, but not close a deal before the clock moves from strategy to survival.